European Innovation Council

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Onego Bio is a biotechnology company focused on producing animal-free egg white protein through precision fermentation. Their innovative ingredient, Bioalbumen, offers a sustainable alternative with the same taste and nutritional profile as traditional egg whites, while boasting superior functional characteristics and over a 90% reduction in environmental impact compared to conventional egg production. Onego Bio's scalable technology meets the growing demand from the food industry for stable, sustainable functional ingredients. The company has received recognition for its contributions to sustainability, including being named a winner of Fast Company’s 2023 World Changing Ideas awards. Additionally, Onego Bio is a co-founder of two industry associations, the Precision Fermentation Alliance and Food Fermentation Europe, further solidifying its role in advancing sustainable food technologies.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

NEOGAP Therapeutics is a clinical-stage biopharmaceutical startup focused on immuno oncology. Their pharmaceutical product, personalized tumor trained lymphocytes, offers even one customized cell treatment that is meant to precisely target and destroy cancer in a tailored environment, with very minor side effects.

ResoTher Pharma is a Copenhagen-based biotechnology company specializing in the development of peptide-based drugs aimed at treating cardiovascular and inflammatory disorders characterized by neutrophil-driven inflammation. The company focuses on leveraging the endogenous immunomodulator Annexin A1 to create therapeutic solutions that act as resolution therapy for diseases associated with innate immune activation. By targeting a specific G-protein coupled receptor on leukocytes, ResoTher Pharma's patented peptide drugs aim to mimic the body's natural mechanisms for resolving inflammation and promoting tissue healing, addressing significant unmet medical needs in the treatment of these conditions.

Cellevate AB is a biotech company based in Lund, Sweden, founded in 2014. It specializes in developing advanced 3D cell culture systems utilizing nanofiber scaffolds known as 3D NanoMatrix. These scaffolds facilitate the creation of realistic in-vitro models, which are essential for scientific research and development across various fields, including automotive, construction, defense, electronics, energy, environment, and healthcare. Cellevate's platform employs a patented manufacturing process to produce consistent and porous networks of nanofibers, enhancing the effectiveness of cell culture systems and supporting upstream bioprocessing efforts.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

Pulse is a platform for furthering our understanding of bioprinting and its applications in space exploration and medicine.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Cellbox Solutions is a technology company that specializes in innovative logistical solutions for the global BioMed industry. The company has developed a carbon dioxide incubator aimed at enhancing the storage, isolation, handling, and analysis of biological materials. This incubator supports the proper management of living cells, facilitating their storage, reproduction, transportation, and analysis. By enabling the safe transport of living cells via roads, rails, or airways, Cellbox Solutions assists healthcare providers in their efforts to deliver advanced therapies and improve patient treatment outcomes.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Abbelight specializes in super-resolution microscopy and membrane imaging, focusing on single molecule localization microscopy to enhance biological research. The company integrates consumables, hardware, and software to deliver advanced scientific solutions, allowing researchers in biology, pharmacology, and environmental studies to utilize super-resolved fluorescence microscopy for improved observation of biological samples. Abbelight aims to democratize access to these sophisticated techniques by simplifying their application while maintaining high performance standards. To support scientists throughout the research process, Abbelight offers expertise in sample preparation and result analysis, providing a comprehensive approach that combines chemistry, computer science, and optical instruments.

Inobiostar focuses on research and experimental development services.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Smart Immune is a clinical-stage biotechnology company focused on developing innovative hematopoietic stem cell-based therapies aimed at improving the prognosis and quality of life for patients with serious diseases. The company's primary program utilizes T cell progenitors, known as ProTcells, which are designed to facilitate a rapid and safe immune recovery following transplantation. This therapy seeks to provide a polyclonal immune response, enhancing the body's ability to combat cancers and infections. Additionally, Smart Immune plans to complement its core offerings with advancements in targeted conditioning, gene therapy, and genome editing, thereby creating next-generation treatments for a range of inherited blood disorders and hematological malignancies.

Samplix is a biotechnology company based in Herlev, Denmark, focused on single-molecule sample preparation for DNA and RNA. It has developed the Xdrop™ technology, which utilizes a unique “water-oil-water” droplet system to create millions of reaction chambers for handling individual DNA molecules. This innovative approach allows for targeted enrichment of large DNA fragments and enables researchers to sequence specific genetic regions effectively. Samplix's technology addresses the limitations of existing multi-molecule preparation methods, providing enhanced precision and sensitivity while simplifying the sample preparation process. Its solutions empower scientists to make informed research decisions, particularly in applications related to virus integration and CRISPR editing.

Inbiome is a biotechnology company specializing in molecular diagnostics. It has developed proprietary molecular culture technology that accelerates bacterial testing and microbiome analysis. The company aims to advance clinical microbiology by focusing on microbial detection and product development, enabling more accurate and timely diagnoses, and ultimately improving patient outcomes.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Iris.ai offers an AI-powered science assistant designed to enhance the efficiency of research and development departments by facilitating the navigation of scientific literature. Its primary product, RSpace, features advanced search capabilities, smart filters, reading list analysis, auto-generated summaries, and automated data extraction, enabling users to systematically organize information. By leveraging natural language processing algorithms, Iris.ai addresses the challenges of factuality tracking in AI, providing tools that enhance the accuracy and reliability of scientific research. This platform is aimed at both corporate R&D teams and academic researchers, allowing them to uncover new scientific insights that go beyond traditional human capabilities.

Iris.ai offers an AI-powered science assistant designed to enhance the efficiency of research and development departments by facilitating the navigation of scientific literature. Its primary product, RSpace, features advanced search capabilities, smart filters, reading list analysis, auto-generated summaries, and automated data extraction, enabling users to systematically organize information. By leveraging natural language processing algorithms, Iris.ai addresses the challenges of factuality tracking in AI, providing tools that enhance the accuracy and reliability of scientific research. This platform is aimed at both corporate R&D teams and academic researchers, allowing them to uncover new scientific insights that go beyond traditional human capabilities.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

iOnctura is a biopharmaceutical company that develops novel therapeutics aimed at addressing immunosuppression within the tumor microenvironment, which can hinder effective cancer treatment. The company focuses on creating next-generation biomolecules to enhance existing immune checkpoint therapies, ultimately aiming to improve patient outcomes in cancer treatment. Through collaborations with Merck and Cancer Research Technology, iOnctura is advancing a pipeline of preclinical molecules designed to be used in combination with immuno-oncology therapies. With access to state-of-the-art drug discovery laboratories and a network of academic partners, iOnctura is strategically positioned to develop innovative combination therapies in cancer immunology, ensuring a focused approach to tackling the complexities of cancer and fibrosis.

Vésale Pharma is a company dedicated to producing pharmaceutical products that aim to enhance health and well-being for individuals throughout their lives. Collaborating with internationally recognized research organizations, Vésale Pharma focuses on developing innovative healthcare solutions tailored to diverse needs. Their product range addresses various health concerns, including dermatology, gastroenterology, women's health, immunity, and pregnancy. Notably, the company's offerings are designed to have no side effects and are suitable for all body types, ensuring that patients can maintain their fitness and overall health.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Herantis Pharma is a biotechnology company focused on addressing unmet clinical needs through the development of disease-modifying therapies for Parkinson's disease. The company's primary development program centers on HER-096, a peptidomimetic molecule engineered to preserve the biological activity of the neuroprotective CDNF protein. By targeting the underlying mechanisms of the disease, Herantis Pharma aims to provide innovative treatment options for patients suffering from Parkinson's disease.

Actome specializes in emulsion coupling technology and interactome technology to advance life science research and personalized medicine. The company has developed a proprietary method that allows for the detection of single protein molecules and protein interaction complexes. By translating protein status into DNA barcodes using DNA-labeled antibodies, Actome enables detailed molecular biological research. This innovative approach aids clients in quantifying proteins, analyzing protein interactions, and studying post-translational modifications in biological samples. Through its technologies, Actome contributes to advancements in pharmaceuticals and the development of novel personalized therapies.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

FOx Biosystems is a biotechnology company focused on enhancing biomolecular interaction analysis for life science research and industry. Founded in 2017 by Filip Delport and Jeroen Lammertyn, and based in Temse, Oost-Vlaanderen, Belgium, the company specializes in developing custom applications, including probes and devices, to support various research needs. FOx Biosystems employs real-time, label-free analysis technology that offers significant advantages over traditional biomolecular analysis tools, such as ease of use, speed, and cost-effectiveness. This technology enables healthcare companies and researchers to obtain high-quality biomolecular data, including concentration measurements, affinity data, and kinetic data, ultimately aiming to transform the life sciences sector.

Enduro Genetics is a technology provider that specializes in enhancing large-scale fermentations through its proprietary synthetic biology technology. The company focuses on improving the performance of fermentation processes by developing a genetic plugin technology that is free of antibiotic resistance genes. This innovation allows for higher yields by enriching spontaneous high producers within the fermentation population, facilitating the production of complex or cellular inhibit products by addressing strain instability. By maximizing the performance of cells derived from production strains, Enduro aims to bolster the competitiveness of both current and future green bioproduction initiatives.

Xenikos is focused on developing innovative immunotherapy treatments aimed at addressing serious immune diseases and complications arising from transplants. The company specializes in anti-T-cell antibodies that can effectively reset the immune system. This therapeutic approach involves injecting a specific agent that targets and eliminates adult T cells, particularly those that are activated, thereby enhancing treatment outcomes for patients. By leveraging this unique mechanism, Xenikos seeks to restore health and improve the quality of life for individuals facing significant immune-related challenges.

Cherry Biotech is a biomedical technology company specializing in Organ-on-Chip systems that facilitate drug discovery and personalized medicine. The company develops advanced microfluidic technologies to culture and replicate human organs under various physiological and pathological conditions. Additionally, Cherry Biotech provides temperature controllers to enable rapid temperature changes and next-generation 3D cell culture technologies. These innovations assist clinicians in accurately mimicking the human cellular microenvironment, which is essential for drug development and toxicity assessments.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Arthex Biotech S.L. is a biotechnology company based in Paterna, Spain, that specializes in the development of antisense RNA therapies for genetic diseases. Founded in 2019 as a spin-off from the University of Valencia, the company focuses on addressing unmet medical needs through innovative treatments targeting microRNAs, which are implicated in various disorders, including neuromuscular diseases. With a team experienced in drug discovery and strong support from leading scientific and clinical advisors, Arthex Biotech aims to provide effective therapies for patients suffering from rare and challenging conditions.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Hemispherian is a biotechnology company focused on developing innovative treatments for various types of cancer, particularly aggressive forms such as glioblastoma multiforme. The firm specializes in personalized cancer therapies and is working on a new class of small-molecule drugs designed to address significant unmet medical needs in oncology. By formulating these advanced treatments, Hemispherian aims to provide physicians with access to novel therapeutic options that can improve patient outcomes in the fight against cancer.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Immunethep is a biotechnology company focused on developing innovative therapies for immune system-related diseases. Originating as a spin-off from the University of Porto, the company leverages proprietary technology to address significant unmet medical needs. Immunethep has identified a novel mechanism by which various pathogenic bacteria suppress the host immune response. By targeting this mechanism, the company aims to create broad-spectrum anti-bacterial immunotherapies. Among its initiatives, Immunethep is working on neonatal vaccines designed to protect infants from bacterial infections before birth, thereby enhancing their immunity and preventing multi-bacterial infections. Through these advancements, Immunethep strives to improve patient outcomes and contribute to the field of advanced healthcare.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Actome specializes in emulsion coupling technology and interactome technology to advance life science research and personalized medicine. The company has developed a proprietary method that allows for the detection of single protein molecules and protein interaction complexes. By translating protein status into DNA barcodes using DNA-labeled antibodies, Actome enables detailed molecular biological research. This innovative approach aids clients in quantifying proteins, analyzing protein interactions, and studying post-translational modifications in biological samples. Through its technologies, Actome contributes to advancements in pharmaceuticals and the development of novel personalized therapies.

AcouSort is a Swedish company specializing in the development and sale of laboratory products and integrated solutions that utilize ultrasound technology for the separation, washing, and enrichment of biological samples. Its offerings cater to researchers and life science companies, focusing on the automated preparation of samples such as blood cells, bacteria, and extracellular vesicles. The technology is rooted in acoustofluidics research from the esteemed group led by Professor Thomas Laurell at Lund University's Department of Biomedical Engineering. Key products include AcouTrap, AcouWash, and AcouPlasma, which facilitate efficient handling of microscopic particles in microfluidic channels for research and diagnostic applications.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Metafora Biosystems is a biotechnology company focused on developing receptor binding domains (RBDs), which are innovative ligands targeting nutrient transporters. Their technology enables the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. This capability positions Metafora's tools as competitive assets in various segments of the biomarker market, offering unique insights into cellular responses and enhancing understanding of metabolic processes.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Antabio is a private biopharmaceutical company based in Labege, France, focused on developing novel treatments for drug-resistant infections, particularly targeting critical priority pathogens. Founded in 2009, the company specializes in creating antibacterial resistance-breakers that can restore the efficacy of existing antibiotics. Its key innovation includes inhibitors of bacterial metalloenzymes, specifically Metallo ß-lactamases (MBLs), which are designed to be used in combination with carbapenems to address significant treatment gaps in drug-resistant nosocomial infections. Antabio aims to provide health professionals with effective medicinal products to combat life-threatening respiratory infections, including carbapenem-resistant pneumonia and chronic pulmonary diseases. The company has received recognition for its research efforts, including a Wellcome Trust Seeding Drug Discovery Award.

Metafora Biosystems is a biotechnology company focused on developing receptor binding domains (RBDs), which are innovative ligands targeting nutrient transporters. Their technology enables the detection of subtle quantitative changes in cell physiology, reflecting metabolic variations caused by factors such as drugs, genetic mutations, cell culture conditions, and diseases. This capability positions Metafora's tools as competitive assets in various segments of the biomarker market, offering unique insights into cellular responses and enhancing understanding of metabolic processes.

Celeris Therapeutics is an AI-driven drug discovery company focused on developing proximity-inducing compounds (PICs), particularly PIC degraders, to address diseases with significant unmet medical needs, including Parkinson's disease and various cancers. The company utilizes its proprietary Celeris One platform, which employs structure-based geometric deep learning to enhance the design and development of degraders. This platform aids in the prioritization of specific E3 ligases, the design of linkers, and the selection of the most promising compounds for synthesis. Additionally, Celeris Therapeutics operates an automated laboratory that rapidly generates experimental data for further optimization. The company collaborates with pharmaceutical and biotech firms to co-develop small-molecule degrader therapies across various therapeutic areas while also building its own drug pipeline. Celeris Therapeutics maintains offices in Menlo Park, California, and Graz, Austria.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Elicera Therapeutics is a clinical-stage immuno-oncology company based in Sweden, focused on developing innovative cell and gene therapies for cancer treatment. The company’s portfolio includes four drug candidates: ELC-100 and ELC-201, which are oncolytic virus therapies, and ELC-301 and ELC-401, which are CAR T-cell treatments. Additionally, Elicera has developed a universal CAR T-cell technology platform known as iTANK (ELC-001), designed to enhance the effectiveness of CAR T-cell therapies by enabling a multi-targeted approach against solid tumors.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

Cellevate AB is a biotech company based in Lund, Sweden, founded in 2014. It specializes in developing advanced 3D cell culture systems utilizing nanofiber scaffolds known as 3D NanoMatrix. These scaffolds facilitate the creation of realistic in-vitro models, which are essential for scientific research and development across various fields, including automotive, construction, defense, electronics, energy, environment, and healthcare. Cellevate's platform employs a patented manufacturing process to produce consistent and porous networks of nanofibers, enhancing the effectiveness of cell culture systems and supporting upstream bioprocessing efforts.

Ovagen is a biotechnology company specializing in the large-scale production of germ-free chicken eggs and birds, primarily for the pharmaceutical industry. The company's innovative process utilizes a transgenic chicken platform to produce recombinant proteins to Good Manufacturing Practice (GMP) standards. This technology provides pharmaceutical companies with a biosecure and flexible biomanufacturing solution for developing vaccines and therapeutic proteins. In addition to its core offerings, Ovagen also provides Contract Research Services and has expertise in specific poultry and rodent research technologies, as well as in SPF poultry and rodent housing and husbandry.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

TILT Biotherapeutics Ltd is a preclinical stage biotechnology company based in Helsinki, Finland, specializing in the development of genetically modified oncolytic viruses aimed at enhancing cancer treatments. The company's patented technology focuses on using these viruses to improve tumor T-cell therapies, including tumor-infiltrating lymphocyte (TIL) and chimeric antigen receptor (CAR-T) therapies, as well as checkpoint inhibitors. TILT Biotherapeutics is recognized as a leader in the global market for integrating oncolytic viruses with cancer immunotherapy. Their product pipeline includes TILT-123, TILT-234, and TILT-321, which are designed to modify the tumor microenvironment and counteract its suppression of immune responses. The innovative approach has the potential to replicate the successes seen in CAR-T therapy for solid tumors, similar to those achieved in hematological cancers.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

BrainEver focuses on developing innovative therapeutics for neurodegenerative disorders, rooted in the research of Alain Prochiantz and colleagues on brain development and physiology. The company explores the potential of homeoproteins, which are known to regulate neuronal functions throughout life, to enhance the physiological resistance and activity of surviving neurons in patients. This approach aims to improve clinical symptoms in conditions such as Parkinson's disease and amyotrophic lateral sclerosis (ALS). The company is advancing its lead candidate, Engrailed 1 (BREN01), while also working on a pipeline of additional drug candidates targeting other neurodegenerative diseases, including Huntington's disease and optic neuropathies. By developing these novel therapeutics, BrainEver aims to provide effective treatment options for healthcare practitioners and patients affected by these challenging conditions.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company offers a range of services, including the analysis of large, polyploid plant genomes, transcriptome studies, differential gene expression, and functional genome annotation. It also provides reference-free genotyping, DNA methylation analysis, and metagenomic analysis. By applying advanced machine learning models to biological data, Computomics helps researchers accelerate genetic gains and make informed decisions in over 190 projects. The company's goal is to support sustainable agricultural development, enabling clients in agriculture, biotechnology, microbiome research, and metabolomics to derive actionable insights from their genomic data.

Core Biogenesis is a biotechnology company based in Paris, France, established in 2020. It specializes in next-generation recombinant protein production technologies, utilizing proprietary gene editing and plant biotechnology to significantly lower the costs associated with producing growth factors. These growth factors are crucial for applications in the clean meat and cell therapy industries. The company has developed an ultra-scalable bioproduction platform that leverages plants as biofactories, enabling efficient mass production and targeted extraction of valuable bioproducts. This innovative approach not only accelerates production but also enhances the ability to regulate cell growth and increases yields, making it a valuable partner for clients in the healthcare sector.

Scipio Bioscience is a biotechnology company based in Paris, France, founded in 2017. The company specializes in manufacturing benchtop kits that provide a sample preparation solution for single-cell studies. These kits are designed for use in sequencing applications within both clinical and basic research, particularly in the field of transcriptomics. Scipio Bioscience's innovative products enable research laboratories to perform single-cell barcoding in a test tube format, facilitating advanced analysis and research in the life sciences.

Camino Science is a biotechnology company based in Bialystok, Poland, that specializes in molecular biology research. The company develops innovative biotech tools and utilizes artificial intelligence to enhance scientific inquiry and understanding. By integrating advanced technology with biological research, Camino Science aims to contribute to advancements in the field and support the scientific community in its endeavors.

Nagi Bioscience SA, based in Lausanne, Switzerland, specializes in the development and manufacturing of an innovative automated testing device that utilizes microscopic worms for substance testing in pharmaceutical, chemical, and cosmetic industries. Their flagship product, the Caenorhabditis elegans-on-chip, integrates the use of these organisms for in vivo testing with a fully automated platform for in vitro culture, treatment, and analysis. This technology facilitates comprehensive toxicity testing, drug discovery, and anthelmintic testing applications, allowing clients to evaluate biological responses observable only at the whole-organism level. Nagi Bioscience aims to transform traditional testing methodologies by introducing its unique "Organism-on-Chip" technology.

Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.

VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.

VBL Therapeutics is a clinical-stage biotechnology company focused on developing innovative treatments for cancer and immune-inflammatory diseases. The company’s clinical pipeline features two proprietary platform technologies that utilize the body’s natural biological and genetic mechanisms. Their lead product candidate, VB-111, is a gene-based biologic aimed at treating solid tumors, particularly recurrent glioblastoma, an aggressive brain cancer. In addition to its oncology efforts, VBL is also working on therapies for anti-inflammatory conditions through its Lecinoxoid platform technology. The company is dedicated to advancing first-in-class treatments that address significant unmet medical needs.

EVerZom is a nanomedicine biotech company based in Paris, France, specializing in the large-scale manufacturing of extracellular vesicles. Founded in 2019, the company has developed a unique, GMP-compliant bioproduction platform aimed at pharmaceutical companies. This platform enables the production of various types of extracellular vesicles, including exosomes, microvesicles, and apoptotic bodies, which are essential for intercellular communication. EVerZom's products possess protective and reparative properties, making them valuable therapeutic tools in regenerative medicine and drug delivery. The company's technology is designed to assist healthcare professionals in addressing organ failure and restoring function and homeostasis.

Computomics GmbH is a bioinformatics company based in Tübingen, Germany, specializing in molecular data analysis for crop biotechnology and agricultural research. Founded in 2012, the company offers a range of services, including the analysis of large, polyploid plant genomes, transcriptome studies, differential gene expression, and functional genome annotation. It also provides reference-free genotyping, DNA methylation analysis, and metagenomic analysis. By applying advanced machine learning models to biological data, Computomics helps researchers accelerate genetic gains and make informed decisions in over 190 projects. The company's goal is to support sustainable agricultural development, enabling clients in agriculture, biotechnology, microbiome research, and metabolomics to derive actionable insights from their genomic data.

enGenome is a bioinformatics company that specializes in genomic interpretation and the development of software aimed at diagnosing genetic diseases. By providing accurate omics-based reports to physicians, enGenome improves the processes of diagnosis and treatment for patients. Their platform automates the interpretation of genetic variants, reduces the occurrence of variants of uncertain significance (VUS), and reports supporting evidence, allowing geneticists to identify pathogenic genomic variants efficiently and accurately. This focus on precision aids in enhancing the overall quality of healthcare for individuals with genetic conditions.

LiMM Therapeutics is a biopharmaceutical company focused on developing therapeutic agents aimed at addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal and innate lymphoid cells to create innovative products that aim to preserve health and improve patient outcomes. By bridging discoveries in neural sensing and immunology, LiMM Therapeutics seeks to unlock new therapeutic solutions that enhance immune regulation and combat infections. Through its research and development efforts, the company aspires to provide healthcare professionals with a pipeline of novel treatments to better manage various health conditions.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that specializes in the development of species-specific therapeutic antibodies for companion animals, particularly dogs. The company focuses on addressing serious diseases in pets and aims to extend its therapeutic offerings to other animal species. Adivo utilizes a fully synthetic, dog-specific drug library to select antibodies with optimal properties through phage display technology. As a spin-off of MorphoSys AG, Adivo benefits from extensive expertise in the development of human therapeutic antibodies, which the team applies to advance veterinary medicine.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that specializes in the development of species-specific therapeutic antibodies for companion animals, particularly dogs. The company focuses on addressing serious diseases in pets and aims to extend its therapeutic offerings to other animal species. Adivo utilizes a fully synthetic, dog-specific drug library to select antibodies with optimal properties through phage display technology. As a spin-off of MorphoSys AG, Adivo benefits from extensive expertise in the development of human therapeutic antibodies, which the team applies to advance veterinary medicine.

Next Generation Sensors is a biotech business that creates mass spectrometers for commercial uses in the life sciences. Finding rapid, accurate screening information for potential health, security, and environmental hazards relies on. By bringing the lab to the sample with portable, sensitive, accurate, and user-friendly technology for quick detection of dangerous compounds in our food, bodies, and environment, offers answers for a safer future.

Sequentia Biotech, founded in 2013 by Walter Sanseverino and Riccardo Aiese Cigliano, is a bioinformatics company based at the UAB Research Park. The company specializes in transforming genomic data into actionable insights for various sectors, including academic research, plant and animal breeding, and biomedicine. Sequentia collaborates with over 30 public and private research centers, universities, and companies, participating in more than 160 research and development projects. The company offers a range of services, including cloud software, custom software solutions, and bioinformatics consulting, aimed at advancing healthcare, agriculture, and environmental sciences. Sequentia Biotech also maintains two open-source biodata banks and has developed an award-winning research initiative called Tricopharming. The founders have contributed significantly to the field, with over 40 scientific publications in prestigious journals.

Epigene Labs SAS, founded in 2019 and headquartered in Paris, France, with an additional office in Boston, Massachusetts, develops a biotechnology platform that harnesses advanced artificial intelligence to transform genomic data into actionable insights for precision oncology. The platform addresses the challenges of aggregating, analyzing, and visualizing extensive genomic datasets, which are crucial for advancing precision oncology. By integrating proprietary data from partners with publicly available information, Epigene Labs provides medical researchers with user-friendly analytics and insights that facilitate drug development and research in cancer treatment. The company focuses on forming value-based partnerships with leading cancer centers and prominent biotech firms to enhance the efficacy of oncology solutions.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex diseases. RemedyBio has developed innovative technology that accelerates and scales single-cell analysis, which plays a crucial role in advancing treatments in areas such as immuno-oncology, autoimmune diseases, and infectious diseases. By leveraging this technology, RemedyBio seeks to provide the healthcare industry with more effective therapeutic and diagnostic solutions.

Synovance is focused on advancing the bio-based economy through the development of plant-derived resources for a variety of applications, including fuels, chemicals, materials, food, and feed. The company specializes in producing bio-based textile dyes and employs engineered organisms capable of efficiently converting biomass. By developing customized strains and assembling tailored secondary genomes, Synovance enables manufacturing industries to meet specific functional requirements across diverse applications. This innovative approach positions Synovance as a leader in sustainable practices, promoting environmentally responsible solutions for various sectors, including the textile industry.

DELMIC specializes in correlative light and electron microscopy technology, focusing on applications in life and materials science research. The company offers a range of services, including cathodoluminescence, automated cryo-electron tomography workflows, and efficient electron microscopy solutions. These services are designed to enhance research capabilities by providing reliable and high-throughput methodologies, enabling researchers and organizations to gain insights more quickly and effectively. Through its innovative tools and integrated microscopy approaches, DELMIC aims to facilitate advancements in scientific research.

Hoba Therapeutics is focused on developing innovative biopharmaceuticals aimed at treating neuropathic pain and central nervous system disorders. The company is advancing a novel therapeutic protein designed to target specific cells, providing medical practitioners with effective, safe, and disease-modifying treatment options. Hoba Therapeutics aims to offer relief and prevention for chronic pain and hearing loss, addressing significant medical needs for patients suffering from these conditions.

Qubit Pharmaceuticals is a Paris-based company founded in 2020 that specializes in drug discovery technology. Established through collaboration among notable institutions such as CNAM, CNRS, the University of Texas at Austin, Sorbonne University, and Washington University, it draws on over 20 years of research and development recognized by prestigious awards. The company has developed a drug discovery simulation platform that aims to reduce both the cost and duration of preclinical drug development. Utilizing proprietary force field models and molecular dynamics calculations, the platform conducts virtual screening and visualization to identify promising drug candidates. This innovative approach leverages quantum physics to support biopharmaceutical companies in accelerating their research and development efforts.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

Synovance is focused on advancing the bio-based economy through the development of plant-derived resources for a variety of applications, including fuels, chemicals, materials, food, and feed. The company specializes in producing bio-based textile dyes and employs engineered organisms capable of efficiently converting biomass. By developing customized strains and assembling tailored secondary genomes, Synovance enables manufacturing industries to meet specific functional requirements across diverse applications. This innovative approach positions Synovance as a leader in sustainable practices, promoting environmentally responsible solutions for various sectors, including the textile industry.

Developer of microbiome analysis technology designed to monitor the microbiome status and function and quantify its impact on all aspects of human life. The company's technology simplifies, accelerates, and democratizes microbiome analysis to precisely measure the composition and dynamics of the microbiome by uncovering its role in human health and the environment, enabling researchers to access genetic analysis devices to analyze the full genetic makeup of microbiomes.

Deep Branch Biotechnology Ltd., founded in 2018 and based in Nottingham, UK, specializes in carbon recycling services aimed at creating sustainable ingredients for food and feed. By utilizing clean and renewable carbon and energy sources, the company employs a proprietary gas fermentation platform that leverages sustainable feedstocks to produce bio-based products with a significantly reduced carbon footprint. Deep Branch focuses on customer-driven research and development, enabling it to swiftly deliver innovative solutions to meet the growing demand for sustainable food systems. The company collaborates with local suppliers of strategic raw materials, fostering local economies while ensuring a reliable input supply. With a clear roadmap for scaling its operations, Deep Branch has formed strong partnerships across the value chain and has integrated effectively with carbon dioxide suppliers to optimize the deployment of its technology. By producing ingredients that require no arable land and minimal water, Deep Branch is addressing climate change and biodiversity loss, contributing to a more sustainable future without compromising on nutritional quality.

Exeliom is a clinical-stage biopharmaceutical company based in Dijon, France, focused on developing innovative microbial therapies that utilize commensal bacteria as therapeutic agents. Founded in 2016, Exeliom aims to unlock the therapeutic potential of gut microbiota to enhance health and longevity. The company specializes in creating a new class of medicines known as Live Biotherapeutics, which are designed to deliver microbiome-based immunotherapy for conditions such as inflammatory bowel diseases and cancer, with an initial focus on Crohn's Disease. By harnessing the role of microbiota in the immune system, Exeliom strives to provide patients with advanced treatments that improve their quality of life.

LiMM Therapeutics is a biopharmaceutical company focused on developing therapeutic agents aimed at addressing inflammatory, infectious, and metabolic diseases. The company leverages the molecular interactions between neuronal and innate lymphoid cells to create innovative products that aim to preserve health and improve patient outcomes. By bridging discoveries in neural sensing and immunology, LiMM Therapeutics seeks to unlock new therapeutic solutions that enhance immune regulation and combat infections. Through its research and development efforts, the company aspires to provide healthcare professionals with a pipeline of novel treatments to better manage various health conditions.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in the development of biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients. The company's work is grounded in extensive scientific research conducted at Uppsala University and the Swedish University of Agriculture.

Ilya Pharma AB, established in 2016 and headquartered in Uppsala, Sweden, specializes in the development of biological drugs for treating skin and mucosal wounds. The company's innovative approach involves genetically modifying lactic acid bacteria, commonly found in yogurt, to produce substances that accelerate wound healing. Ilya Pharma focuses on both acute and chronic wounds, with a particular emphasis on addressing the unique challenges faced by diabetic patients. The company's work is grounded in extensive scientific research conducted at Uppsala University and the Swedish University of Agriculture.

RemedyBio is an immunology-focused discovery and development company located in Dublin, Ireland. The company specializes in creating therapeutics aimed at enhancing immunotherapies for complex diseases. RemedyBio has developed innovative technology that accelerates and scales single-cell analysis, which plays a crucial role in advancing treatments in areas such as immuno-oncology, autoimmune diseases, and infectious diseases. By leveraging this technology, RemedyBio seeks to provide the healthcare industry with more effective therapeutic and diagnostic solutions.

Ability Pharmaceuticals is a drug discovery and development company based in Barcelona, Spain. It develops human therapeutics targeting cell membranes to treat cancer and other indications with unmet medical needs. Ability Pharmaceuticals is focused on developing new drugs for the treatment of lung cancer and pancreatic cancer. The company develops Lipid Analogue Therapeutics, a new drug class that modifies the composition of the cell membrane and displays a capacity to influence the local organization of lipid structures in the cell membrane, inducing the formation of non-lamellar phase structures. Its development pipeline includes ABTL0812 product in preclinical development; and ABTL1014, a drug candidate in preclinical characterization.

SOMAprobes focuses on the development and commercialization of innovative diagnostic solutions that leverage the biology of nucleases. The company specializes in in vitro diagnostic tests aimed at identifying diseases that are often challenging to diagnose using traditional methods. Among its offerings are activatable contrast agents designed for MRI detection of bacterial pathogens, particularly at the onset of infectious diseases such as cancer, bone infections, and prosthetic joint infections. These advancements provide healthcare professionals with essential tools for rapid decision-making, improving patient outcomes through timely and accurate diagnosis.

Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.

SOMAprobes focuses on the development and commercialization of innovative diagnostic solutions that leverage the biology of nucleases. The company specializes in in vitro diagnostic tests aimed at identifying diseases that are often challenging to diagnose using traditional methods. Among its offerings are activatable contrast agents designed for MRI detection of bacterial pathogens, particularly at the onset of infectious diseases such as cancer, bone infections, and prosthetic joint infections. These advancements provide healthcare professionals with essential tools for rapid decision-making, improving patient outcomes through timely and accurate diagnosis.

SiriusXT Limited, based in Dublin, Ireland, specializes in the development and manufacturing of a soft x-ray microscope known as the SXT system. Founded in 2015, the company primarily serves researchers in disease research and drug discovery. The microscope employs a vacuum-based laser-produced plasma light source, enabling high-resolution imaging of the 3D internal structure of cells in their native, fully hydrated state. This technology is akin to a CT scan for cells, allowing for detailed visualization without the need for stains or contrast agents. The SXT system is particularly beneficial for disease researchers, pharmaceutical companies, and biotechnologists, as it facilitates the understanding of disease pathways, protein-drug interactions, and bio-engineering processes. As the first high-throughput, bench-top soft x-ray microscope, SiriusXT's system can produce full cell 3D tomographs in a matter of minutes, significantly advancing imaging capabilities in scientific research.

Betalin Therapeutics is a privately-held company focused on developing a cell therapy solution for insulin-dependent diabetes through its Engineered Micro-Pancreas (EMP) technology. The EMP combines harvested pancreatic islets, known as Islets of Langerhans, with a proprietary biological micro-environment designed to support these cells. After achieving promising in-vitro results and preliminary in-vivo outcomes, the company is working to further optimize its therapy in animal models. Betalin Therapeutics aims to complete the submission of its Investigational New Drug application to the FDA and advance to clinical trials, with the goal of providing an alternative to traditional insulin therapy and eliminating the need for insulin injections and glucose testing in diabetes patients.